Common Contracts
5 similar Revenue Interest Financing Agreement contracts by Allurion Technologies Holdings, Inc., Chiasma, Inc, Karyopharm Therapeutics Inc., others
REVENUE INTEREST FINANCING AGREEMENT among ALLURION TECHNOLOGIES, INC. and RTW MASTER FUND, LTD., RTW INNOVATION MASTER FUND, LTD., and RTW VENTURE FUND LIMITED Dated February 9, 2023Revenue Interest Financing Agreement • February 10th, 2023 • Allurion Technologies Holdings, Inc. • Blank checks • New York
This Revenue Interest Financing Agreement (this “Agreement”) dated as of February 9, 2023 (the “Effective Date”) is among Allurion Technologies, Inc., a Delaware corporation (the “Company”), and RTW Master Fund, Ltd., an exempted company incorporated in the Cayman Islands with limited liability, RTW Innovation Master Fund, Ltd., an exempted company incorporated in the Cayman Islands with limited liability, and RTW Venture Fund Limited, an investment company limited by shares incorporated under the laws of Guernsey (each and collectively, the “Investor”). Each of the Company and the Investor is referred to in this Agreement as a “Party” and collectively as the “Parties”.
REVENUE INTEREST FINANCING AGREEMENT by and among RHYTHM PHARMACEUTICALS, INC., as the Company, ENTITIES MANAGED BY HEALTHCARE ROYALTY MANAGEMENT, LLC, as the Investors, and HCR COLLATERAL MANAGEMENT, LLC, as the Investor Representative Dated June 16,...Revenue Interest Financing Agreement • August 3rd, 2022 • Rhythm Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This REVENUE INTEREST FINANCING AGREEMENT (this “Agreement”) dated as of June 16, 2022 (the “Effective Date”) is by and among RHYTHM PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), the entities managed by HEALTHCARE ROYALTY MANAGEMENT, LLC listed on the signature pages hereto (the “Investors”), and HCR COLLATERAL MANAGEMENT, LLC, a Delaware limited liability company (the “Investor Representative”), solely in its capacity as agent for, and representative of, the Investors. Each of the Company and the Investors are referred to in this Agreement as a “Party” and collectively as the “Parties”.
REVENUE INTEREST FINANCING AGREEMENT between SPERO THERAPEUTICS INC., as the Company, and ENTITIES MANAGED BY HEALTHCARE ROYALTY MANAGEMENT, LLC, as the Investors Dated September 29, 2021Revenue Interest Financing Agreement • September 30th, 2021 • Spero Therapeutics, Inc. • Pharmaceutical preparations • New York
This REVENUE INTEREST FINANCING AGREEMENT (this “Agreement”) dated as of September 29, 2021 (the “Effective Date”) is between SPERO THERAPEUTICS INC., a Delaware corporation (the “Company”), and the entities managed by HEALTHCARE ROYALTY MANAGEMENT, LLC listed on the signature pages hereto (the “Investors”). Each of the Company and the Investors are referred to in this Agreement as a “Party” and collectively as the “Parties”.
REVENUE INTEREST FINANCING AGREEMENT between CHIASMA, INC., as the Company, and HEALTHCARE ROYALTY PARTNERS IV, L.P., as Investor Dated April 7, 2020Revenue Interest Financing Agreement • May 7th, 2020 • Chiasma, Inc • Pharmaceutical preparations • New York
REVENUE INTEREST FINANCING AGREEMENT between KARYOPHARM THERAPEUTICS INC., as the Company, and HEALTHCARE ROYALTY PARTNERS III, L.P. AND HEALTHCARE ROYALTY PARTNERS IV, L.P., collectively as Investor Dated September 14, 2019Revenue Interest Financing Agreement • November 4th, 2019 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • New York
This REVENUE INTEREST FINANCING AGREEMENT (this “Agreement”) dated as of September 14, 2019 (the “Effective Date”) is between KARYOPHARM THERAPEUTICS INC., a Delaware corporation (the “Company”), and HEALTHCARE ROYALTY PARTNERS III, L.P. and HEALTHCARE ROYALTY PARTNERS IV, L.P. Each of the Company and any Investor are referred to in this Agreement as a “Party” and collectively as the “Parties”.
